Multikine still awaits a commercial breakthrough. CEL-SCI’s Saudi deal tests whether regional oncology access can change that trajectory.
Saudi localization gives Co-Diagnostics a new opening. The test is whether CoMira can turn a factory lease into diagnostics traction.